

Press release

Stockholm, June 30, 2022

New number of votes in Tobii

The number of votes in Tobii AB (publ) has increased as a result of the conversion of a total of 230,972 class C-shares to a total of 230,972 ordinary shares.

The conversion was carried out in order to deliver ordinary shares to participants and to cover cash costs and social contribution costs in relation to the company's incentive program originally adopted at the annual general meeting in 2020. The total number of votes in the company has therefore increased while the total number of shares remain unchanged.

Today, the last trading day of the month, there are in total 107,258,458 shares, of which 105,916,085 are ordinary shares and 1,342,373 are class C-shares, and there are in total 106,050,322 votes in the company. The number of ordinary shares has increased with 230,972 ordinary shares and the number of class C-shares has decreased with 230,972 class C-shares. The number of votes has increased with 207,875 votes. The share capital has remained unchanged at approximately SEK 778,368 after.

This information is information that Tobii AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication on June 30, 2022, at 17.30 p.m. CEST.

Contact

Henrik Mawby, Investor Relations, Tobii AB, phone: +44 74 94 074 006, email: henrik.mawby@tobii.com

About Tobii

Tobii is the global leader in eye tracking and pioneer of attention computing. We are on a mission to improve the world with technology that understands human attention and intent. Creating tech for a better future, our technologies and solutions apply to areas such as scientific studies and research, healthcare, assistive devices, education and training, gaming, extended reality, automotive, and many more. Tobii's eye tracking is used by thousands of enterprises, universities, and research institutes around the globe. Headquartered in Sweden, Tobii is listed on Nasdaq Stockholm (TOBII). For more: www.tobii.com.